62 related articles for article (PubMed ID: 30006755)
21. Mucositis with anti-EGFR monoclonal antibody in cancer patients: a meta-analysis of randomized controlled trials.
Li J; Xie J
Jpn J Clin Oncol; 2018 Aug; 48(8):718-727. PubMed ID: 29893861
[TBL] [Abstract][Full Text] [Related]
22. Skin Toxicities with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Cancer Patients: A Meta-Analysis of Randomized Controlled Trials.
Sun W; Li J
Cancer Invest; 2019; 37(6):253-264. PubMed ID: 31303065
[TBL] [Abstract][Full Text] [Related]
23. Skin toxicity with anti-EGFR monoclonal antibody in cancer patients: a meta-analysis of 65 randomized controlled trials.
Li J; Yan H
Cancer Chemother Pharmacol; 2018 Oct; 82(4):571-583. PubMed ID: 30006755
[TBL] [Abstract][Full Text] [Related]
24. Diarrhea with epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients: A meta-analysis of randomized controlled trials.
Li J; Gu J
Crit Rev Oncol Hematol; 2019 Feb; 134():31-38. PubMed ID: 30771871
[TBL] [Abstract][Full Text] [Related]
25. Risk of grade 3-4 diarrhea and mucositis in colorectal cancer patients receiving anti-EGFR monoclonal antibodies regimens: A meta-analysis of 18 randomized controlled clinical trials.
Miroddi M; Sterrantino C; Simonelli I; Ciminata G; Phillips RS; Calapai G
Crit Rev Oncol Hematol; 2015 Nov; 96(2):355-71. PubMed ID: 26160607
[TBL] [Abstract][Full Text] [Related]
26. Hand-foot skin reaction with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: A systematic review and meta-analysis.
Li J; Gu J
Crit Rev Oncol Hematol; 2017 Nov; 119():50-58. PubMed ID: 29065985
[TBL] [Abstract][Full Text] [Related]
27. Risk of severe rash in cancer patients treated with EGFR tyrosine kinase inhibitors: a systematic review and meta-analysis.
Zhang X; Ran YG; Wang KJ
Future Oncol; 2016 Dec; 12(23):2741-2753. PubMed ID: 27522860
[TBL] [Abstract][Full Text] [Related]
28. First-line anti-EGFR monoclonal antibodies in panRAS wild-type metastatic colorectal cancer: A systematic review and meta-analysis.
Pietrantonio F; Cremolini C; Petrelli F; Di Bartolomeo M; Loupakis F; Maggi C; Antoniotti C; de Braud F; Falcone A; Iacovelli R
Crit Rev Oncol Hematol; 2015 Oct; 96(1):156-66. PubMed ID: 26088456
[TBL] [Abstract][Full Text] [Related]
29. Recommendations on management of EGFR inhibitor-induced skin toxicity: a systematic review.
Baas JM; Krens LL; Guchelaar HJ; Ouwerkerk J; de Jong FA; Lavrijsen AP; Gelderblom H
Cancer Treat Rev; 2012 Aug; 38(5):505-14. PubMed ID: 22100458
[TBL] [Abstract][Full Text] [Related]
30. Cardiovascular Toxicities with Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors in Cancer Patients: A Meta-Analysis of 77 Randomized Controlled Trials.
Li J; Gu J
Clin Drug Investig; 2018 Dec; 38(12):1109-1123. PubMed ID: 30327999
[TBL] [Abstract][Full Text] [Related]
31. Meta-analysis of dermatological toxicities associated with sorafenib.
Zhang L; Zhou Q; Ma L; Wu Z; Wang Y
Clin Exp Dermatol; 2011 Jun; 36(4):344-50. PubMed ID: 21507035
[TBL] [Abstract][Full Text] [Related]
32. Risk of mucocutaneous toxicities in patients with solid tumors treated with sorafenib: an updated systematic review and meta-analysis.
Abdel-Rahman O; Fouad M
Expert Rev Anticancer Ther; 2014 Jun; 14(6):751-60. PubMed ID: 24666215
[TBL] [Abstract][Full Text] [Related]
33. Risk of mucocutaneous toxicities in patients with solid tumors treated with lapatinib: a systematic review and meta-analysis.
Abdel-Rahman O; Fouad M
Curr Med Res Opin; 2015 May; 31(5):975-86. PubMed ID: 25708852
[TBL] [Abstract][Full Text] [Related]
34. Relationship between skin rash and outcome in non-small-cell lung cancer patients treated with anti-EGFR tyrosine kinase inhibitors: a literature-based meta-analysis of 24 trials.
Petrelli F; Borgonovo K; Cabiddu M; Lonati V; Barni S
Lung Cancer; 2012 Oct; 78(1):8-15. PubMed ID: 22795701
[TBL] [Abstract][Full Text] [Related]
35. Antibiotic prophylaxis for skin toxicity induced by antiepidermal growth factor receptor agents: a systematic review and meta-analysis.
Petrelli F; Borgonovo K; Cabiddu M; Coinu A; Ghilardi M; Lonati V; Barni S
Br J Dermatol; 2016 Dec; 175(6):1166-1174. PubMed ID: 27214209
[TBL] [Abstract][Full Text] [Related]
36. Risk of hand-foot skin reaction with sorafenib: a systematic review and meta-analysis.
Chu D; Lacouture ME; Fillos T; Wu S
Acta Oncol; 2008; 47(2):176-86. PubMed ID: 18210295
[TBL] [Abstract][Full Text] [Related]
37. Anti-epidermal growth factor receptor monoclonal antibodies in metastatic colorectal cancer: a meta-analysis.
Song QB; Wang Q; Hu WG
World J Gastroenterol; 2015 Apr; 21(14):4365-72. PubMed ID: 25892888
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of lapatinib and trastuzumab for HER2-positive breast cancer: a systematic review and meta-analysis of randomised controlled trials.
Xu ZQ; Zhang Y; Li N; Liu PJ; Gao L; Gao X; Tie XJ
BMJ Open; 2017 Mar; 7(3):e013053. PubMed ID: 28289045
[TBL] [Abstract][Full Text] [Related]
39. Risk of mucocutaneous toxicities in patients with solid tumors treated with sunitinib: a critical review and meta analysis.
Abdel-Rahman O; Fouad M
Expert Rev Anticancer Ther; 2015 Jan; 15(1):129-41. PubMed ID: 25482593
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
